The estimated Net Worth of Theodore Ashburn is at least $772 millier dollars as of 19 November 2021. Dr Ashburn owns over 32,500 units of Oncorus stock worth over $11,972 and over the last 10 years he sold ONCR stock worth over $0. In addition, he makes $760,128 as Pres et CEO & Director at Oncorus.
Sign up
Dr D ONCR stock SEC Form 4 insiders trading
Dr has made over 3 trades of the Oncorus stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 32,500 units of ONCR stock worth $58,825 on 19 November 2021.
The largest trade he's ever made was exercising 43,707 units of Oncorus stock on 22 October 2021 worth over $79,110. On average, Dr trades about 8,281 units every 32 days since 2014. As of 19 November 2021 he still owns at least 99,352 units of Oncorus stock.
You can see the complete history of Dr Ashburn stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Theodore T. Ashburn M.D., Ph.D. biography
Dr. Theodore T. Ashburn M.D., Ph.D. is the Pres, CEO & Director at Oncorus.
What is the salary of Dr D?
As the Pres et CEO & Director of Oncorus, the total compensation of Dr D at Oncorus is $760,128. There are 1 executives at Oncorus getting paid more, with Stephen W. Harbin having the highest compensation of $815,088.
How old is Dr D?
Dr D is 54, he's been the Pres et CEO & Director of Oncorus since . There are 4 older and 5 younger executives at Oncorus. The oldest executive at Oncorus, Inc. is Dr. Mitchell H. Finer Ph.D., 62, who is the Co-Founder & Non-Exec. Chairman.
What's Dr D's mailing address?
Theodore's mailing address filed with the SEC is C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE, MA, 02139.
Insiders trading at Oncorus
Over the last 4 years, insiders at Oncorus have traded over $1,276,271 worth of Oncorus stock and bought 2,354,001 units worth $35,555,648 . The most active insiders traders include Ansbert Gadicke, Luke Evnin et James E Deerfield Mgmt Hif,.... On average, Oncorus executives and independent directors trade stock every 34 days with the average trade being worth of $15,538. The most recent stock trade was executed by James E Deerfield Mgmt Hif,... on 28 December 2022, trading 336,235 units of ONCR stock currently worth $87,421.
What does Oncorus do?
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What does Oncorus's logo look like?
Complete history of Dr Ashburn stock trades at Dicerna Pharmaceuticals Inc et Oncorus
Oncorus executives and stock owners
Oncorus executives and other stock owners filed with the SEC include:
-
Stephen W. Harbin,
COO & Chief of Staff -
Dr. Theodore T. Ashburn M.D., Ph.D.,
Pres, CEO & Director -
Dr. Theodore T. Ashburn,
Pres, CEO & Director -
Dr. Christophe Queva Ph.D.,
Chief Scientific Officer & Sr. VP of Research -
Stephen Harbin,
COO & Chief of Staff -
Dr. Mitchell H. Finer Ph.D.,
Co-Founder & Non-Exec. Chairman -
Dr. Mitchell H. Finer,
Co-Founder & Exec. Chairman -
Chris German,
Controller -
Brian J. Shea,
Director of Legal Counsel & Corp. Sec. -
Richard J. Wanstall M.B.A.,
CFO, Chief Accounting Officer & Treasurer -
Dr. John Mayer Goldberg M.D.,
Sr. VP of Clinical Devel. -
John McCabe M.B.A.,
CFO, Treasurer & Sec. -
Scott A Canute,
Director -
Rick Wanstall,
CFO and Treasurer -
Theodore Ashburn,
President and CEO -
Christophe Queva,
CSO and SVP, Research -
James E Deerfield Mgmt Hif,...,
-
Luke Evnin,
Director -
Oncology Impact Fund L.P.On...,
-
Ansbert Gadicke,
10% owner -
Mitchell H. Finer,
Director -
Bio Ventures 2014, L.P.Fole...,
-
Spencer Nam,
Director -
Sun States Fund, L.P.Mpm As...,
-
Stephen Harbin,
COO and Chief of Staff -
John P. Mc Cabe,
CFO and Treasurer -
Mary Kay Fenton,
Director -
Eric Rubin,
Director -
Barbara Yanni,
Director -
John Mayer Goldberg,
Chief Medical Officer -
James E Deerfield Mgmt Hif,...,
-
Douglas Fambrough,
Director